BR112014026424A2 - composto, processo para produzir um composto de di-idrato, composto de benzotiofeno, método para prevenir e/ou tratar uma doença, e, composição farmacêutica - Google Patents

composto, processo para produzir um composto de di-idrato, composto de benzotiofeno, método para prevenir e/ou tratar uma doença, e, composição farmacêutica

Info

Publication number
BR112014026424A2
BR112014026424A2 BR112014026424A BR112014026424A BR112014026424A2 BR 112014026424 A2 BR112014026424 A2 BR 112014026424A2 BR 112014026424 A BR112014026424 A BR 112014026424A BR 112014026424 A BR112014026424 A BR 112014026424A BR 112014026424 A2 BR112014026424 A2 BR 112014026424A2
Authority
BR
Brazil
Prior art keywords
compound
producing
dihydrate
disease
treating
Prior art date
Application number
BR112014026424A
Other languages
English (en)
Other versions
BR112014026424B1 (pt
Inventor
Yamashita Hiroshi
Toyofuku Hidekazu
Moriyama Kei
Sota Masahiro
Ito Nobuaki
Eto Ryohei
Kawano Shuuji
Nakamura Takayuki
Ikebuchi Takuma
Minowa Takuya
Yamaguchi Tatsuya
Sato Tetsuya
Hoshika Yusuke
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014026424(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112014026424A2 publication Critical patent/BR112014026424A2/pt
Publication of BR112014026424B1 publication Critical patent/BR112014026424B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

1 / 1 resumo “composto, processo para produzir um composto de di- idrato, composto de benzotiofeno, mã‰todo para prevenir e/ou tratar uma doenã‡a, e, composiã‡ãƒo farmacãšutica” um objetivo da presente invenã§ã£o ã© fornecer um composto que pode ser usado como um agente terapãªutico mais superior para doenã§as do sistema nervoso central. a presente invenã§ã£o fornece um di-idrato de 7-[4-(4- benzo[b]tiofen-4-il-piperazin-1-il)butã³xi]-1h-quinolin-2-ona, ou de um sal deste, e um processo para produzir o mesmo.
BR112014026424-4A 2012-04-23 2013-04-23 Composto, di-idrato, composição, uso do composto diidrato, e, composição farmacêutica BR112014026424B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261636920P 2012-04-23 2012-04-23
US61/636,920 2012-04-23
US201361791378P 2013-03-15 2013-03-15
US61/791,378 2013-03-15
PCT/JP2013/062681 WO2013162046A1 (en) 2012-04-23 2013-04-23 Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Publications (2)

Publication Number Publication Date
BR112014026424A2 true BR112014026424A2 (pt) 2017-06-27
BR112014026424B1 BR112014026424B1 (pt) 2022-09-13

Family

ID=48428584

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026424-4A BR112014026424B1 (pt) 2012-04-23 2013-04-23 Composto, di-idrato, composição, uso do composto diidrato, e, composição farmacêutica

Country Status (37)

Country Link
US (5) US9499525B2 (pt)
EP (1) EP2841431B2 (pt)
JP (1) JP5952917B2 (pt)
KR (1) KR102160395B1 (pt)
CN (1) CN104254530B (pt)
AR (1) AR090774A1 (pt)
AU (1) AU2013253372B2 (pt)
BR (1) BR112014026424B1 (pt)
CA (1) CA2870000C (pt)
CO (1) CO7111315A2 (pt)
CY (1) CY1119103T1 (pt)
DK (1) DK2841431T4 (pt)
EA (1) EA026541B1 (pt)
ES (1) ES2617881T5 (pt)
FI (1) FI2841431T4 (pt)
HK (1) HK1203073A1 (pt)
HR (1) HRP20170242T4 (pt)
HU (1) HUE031997T2 (pt)
IL (1) IL235044B (pt)
IN (1) IN2014DN08867A (pt)
JO (1) JO3325B1 (pt)
LT (1) LT2841431T (pt)
ME (1) ME02619B (pt)
MX (1) MX361723B (pt)
MY (1) MY170220A (pt)
NZ (1) NZ630260A (pt)
PH (1) PH12014502324A1 (pt)
PL (1) PL2841431T3 (pt)
PT (1) PT2841431T (pt)
RS (1) RS55742B2 (pt)
SG (1) SG11201406790VA (pt)
SI (1) SI2841431T2 (pt)
SM (1) SMT201700130B (pt)
TW (1) TWI562991B (pt)
UA (1) UA117456C2 (pt)
WO (1) WO2013162046A1 (pt)
ZA (1) ZA201407477B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
US20170042887A1 (en) 2014-04-22 2017-02-16 Otsuka Pharmaceutical. Co., Ltd. Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
CN106883223B (zh) * 2015-12-16 2021-11-23 北京福元医药股份有限公司 一种Brexpiprazole盐酸盐的纯化方法
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
US10464931B2 (en) 2015-12-28 2019-11-05 Honour (R&D) Process for the preparation of Quinolin-2(1H)-one derivatives
JP2019059672A (ja) * 2015-12-28 2019-04-18 大日本住友製薬株式会社 治療抵抗性うつ病等の治療薬
WO2017134038A1 (en) 2016-02-01 2017-08-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh) * 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
CN106188023A (zh) * 2016-07-04 2016-12-07 山东川成医药股份有限公司 一种依匹唑派的精制方法
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
EP3500247B1 (en) 2016-08-16 2020-05-27 H e x a l Aktiengesellschaft Immediate release tablet of a benzothiophene compound
CN107936005A (zh) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 一种依匹哌唑新晶型ii及其制备方法
CN111233848A (zh) * 2016-12-14 2020-06-05 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
US11072605B2 (en) 2017-02-02 2021-07-27 Hexal Ag Crystalline brexpiprazole
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
CN111440158A (zh) * 2020-03-24 2020-07-24 石药集团中奇制药技术（石家庄）有限公司 一种盐酸依匹哌唑新晶型及其制备方法
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
WO2023067664A1 (ja) * 2021-10-18 2023-04-27 大塚製薬株式会社 ベンゾチオフェン化合物の新規結晶形及びその製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ZA200602347B (en) 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
WO2006030446A1 (en) 2004-09-13 2006-03-23 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
EP2214483B1 (en) * 2007-10-26 2012-06-20 Repligen Corporation Methods of identifying histone deacetylase inhibitors useful for neurological disorders
MX2010008365A (es) * 2008-01-30 2010-08-23 Novartis Ag Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido.
ES2685469T3 (es) 2010-08-24 2018-10-09 Otsuka Pharmaceutical Co., Ltd. Suspensión y composición de torta que contienen derivado de carboestirilo y aceite de silicona y/o derivado de aceite de silicona
JP2012232958A (ja) * 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
BR112014001520B1 (pt) * 2011-07-28 2022-05-10 Otsuka Pharmaceutical Co., Ltd Processo para a produção de composto de benzo[b]tiofeno
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
FI2841431T4 (fi) 2024-04-18
US20210115030A1 (en) 2021-04-22
EP2841431B2 (en) 2024-01-24
LT2841431T (lt) 2017-03-27
HRP20170242T1 (hr) 2017-04-07
HK1203073A1 (en) 2015-10-16
EA201491933A1 (ru) 2015-03-31
JP5952917B2 (ja) 2016-07-13
SG11201406790VA (en) 2014-11-27
US20230049327A1 (en) 2023-02-16
JO3325B1 (ar) 2019-03-13
RS55742B1 (sr) 2017-07-31
IL235044B (en) 2019-05-30
BR112014026424B1 (pt) 2022-09-13
PT2841431T (pt) 2017-03-07
MX2014012527A (es) 2015-03-19
TW201348229A (zh) 2013-12-01
HRP20170242T8 (hr) 2017-09-22
HUE031997T2 (en) 2017-08-28
PL2841431T3 (pl) 2017-06-30
DK2841431T4 (da) 2024-02-12
CA2870000C (en) 2021-02-16
US10407415B2 (en) 2019-09-10
US20200140424A1 (en) 2020-05-07
JP2015514677A (ja) 2015-05-21
IN2014DN08867A (pt) 2015-05-22
ES2617881T3 (es) 2017-06-20
EP2841431B1 (en) 2017-01-04
US20170066752A1 (en) 2017-03-09
KR20150013189A (ko) 2015-02-04
ES2617881T5 (es) 2024-05-22
SI2841431T1 (sl) 2017-03-31
CN104254530A (zh) 2014-12-31
ME02619B (me) 2017-06-20
ZA201407477B (en) 2015-12-23
NZ630260A (en) 2015-09-25
UA117456C2 (uk) 2018-08-10
EA026541B1 (ru) 2017-04-28
WO2013162046A1 (en) 2013-10-31
EP2841431A1 (en) 2015-03-04
PH12014502324B1 (en) 2015-01-12
US20150087655A1 (en) 2015-03-26
AR090774A1 (es) 2014-12-03
SMT201700130B (it) 2017-03-08
HRP20170242T4 (hr) 2024-03-01
AU2013253372B2 (en) 2016-12-08
CY1119103T1 (el) 2018-02-14
RS55742B2 (sr) 2024-04-30
IL235044A0 (en) 2014-12-31
MX361723B (es) 2018-12-14
TWI562991B (en) 2016-12-21
DK2841431T3 (en) 2017-03-06
MY170220A (en) 2019-07-10
AU2013253372A1 (en) 2014-10-30
SI2841431T2 (sl) 2024-03-29
CO7111315A2 (es) 2014-11-10
PH12014502324A1 (en) 2015-01-12
CN104254530B (zh) 2016-09-21
KR102160395B1 (ko) 2020-09-28
CA2870000A1 (en) 2013-10-31
US9499525B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
BR112014026424A2 (pt) composto, processo para produzir um composto de di-idrato, composto de benzotiofeno, método para prevenir e/ou tratar uma doença, e, composição farmacêutica
BR112015008759A2 (pt) método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
BR112015018168A2 (pt) inibidores de rock suaves
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015012295A2 (pt) métodos para tratar um paciente, e, kit para identificar um paciente com câncer
ECSP13012852A (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a.
BR112015005743A2 (pt) derivados tricíclicos de quinoxalina e quinolina
BR112015022340A2 (pt) método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica
BR112014007257A2 (pt) composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
BR112015006305A2 (pt) composições farmacêuticas para prevenir e/ou tratar dislipidemia e para aumentar o colesterol de hdl
BR112014019357A8 (pt) Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp
BR112015000443A2 (pt) derivados de estra-1,3,5(10),16-tetraeno 3-substituídos, processo para a sua produção, preparações farmacêuticas que contêm os mesmos, bem como seu uso para a produção de medicamentos
BR112014016472A2 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
BR112015007360A2 (pt) composição farmacêutica, e, método para a preparação de uma droga de combinação
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112014030288A2 (pt) composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2013, OBSERVADAS AS CONDICOES LEGAIS